DOI: 10.7664/CHE20181116
The Budget Impact Analysis on Introducing Nilainib into Medical Insurance in the Treatment of Patients with Chronic Myelogenous Leukemia Treated with Imatinib or Resistant to Imatinib
HUANG Cheng-feng
SHEN Li-jun
LIU Yue-hua
Machine-generated Keywords：
Publication Date：2018-11-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 59-63 )